General Information of Drug (ID: DMAGX0Q)

Drug Name
REGN5458 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMAGX0Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [3]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [4]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [5]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [6]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [7]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [8]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [9]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [10]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [11]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Idecabtagene vicleucel DMP1QTS Multiple myeloma 2A83 Approved [13]
Belantamab mafodotin DMBT3AI Multiple myeloma 2A83 Approved [14]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [7]
Teclistamab DMGR8JI Multiple myeloma 2A83 Approved [15]
Ciltacabtagene autoleucel DMU2J7Y Multiple myeloma 2A83 Phase 3 [16]
Bb2121 DMB0UF9 Multiple myeloma 2A83 Phase 2 [17]
LCAR-B38M CAR-T Cell DMQZJNA Multiple myeloma 2A83 Phase 2 [18]
Descartes-08 DM63P1W Multiple myeloma 2A83 Phase 2 [19]
Descartes-11 DM1UO4S Multiple myeloma 2A83 Phase 2 [20]
CART-19/BCMA DMVW1GY Multiple myeloma 2A83 Phase 1/2 [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell maturation protein (TNFRSF17) TTZ3P4W TNR17_HUMAN Inhibitor [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
2 A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
5 Clinical pipeline report, company report or official report of Genmab.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
8 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
9 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
10 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
11 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
12 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
15 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
16 ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
19 ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
20 Clinical pipeline report, company report or official report of Cartesian Therapeutics.
21 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT